A 2021 network meta-analysis evaluating the effect of glucose-lowering drugs on the risk of AF/atrial flutter in diabetic patients showed that GLP-1 RA significantly reduced the risk of AF/atrial flutter compared to other glucose-lowering agents [62]. Here, GLP1R is linked to atrial flutter.